The European Commission extended the marketed authorization of Zebinix to treat partial-onset seizures in children above the age of six.

The drug is already authorized for use in adults over the age of 18. It is marketed in Europe and Russia by Bial and by Bial's licensee, Eisai Europe Ltd.

Eisai Europe is an Eisai Co. Ltd. subsidiary.